Teleflex’s Barrigel rectal spacer shows safety, efficacy in new presentation

Teleflex announced the presentation of data supporting the safety and efficacy of Barrigel rectal spacer, the first and only sculptable hyaluronic acid rectal spacer. It is designed to significantly reduce radiation that reaches the rectum during prostate cancer radiation therapy. The data were presented in three abstracta at the American Society for Radiation Oncology 2024 Annual Meeting, September 29 to October 2. Barrigel rectal spacer provides high quality rectal spacing, enabling low dose to the rectum during prostate cancer radiation therapy, with an excellent toxicity and safety profile; and low incidence of rectal wall infiltration, which can be safely reversed using hyaluronidase. Data demonstrate safety and efficacy of Barrigel rectal spacer in stereotactic body radiation therapy for patients undergoing repeat therapy. Physicians deemed Barrigel rectal spacer very easy or easy to implant. No acute or late GI toxicity greater than Grade 2 was reported; 7 acute and 5 late Grade 1 toxicity events were reported.